180 Life Sciences Corp
For the period ended Dec 31, 2023. Filed Mar 25, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 25, 2024
FRMM$2.88-5.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | December 31, | |
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current Assets: | ||
| Cash | $1,975,799 | $6,970,110 |
| Prepaid expenses and other current assets | 1,664,107 | 1,958,280 |
| Total Current Assets | 3,639,906 | 8,928,390 |
| Intangible assets, net | 1,619,570 | 1,658,858 |
| In-process research and development | - | 9,063,000 |
| Total Assets | $5,259,476 | $19,650,248 |
| Liabilities and Stockholders’ Equity | ||
| Current Liabilities: | ||
| Accounts payable | $1,892,611 | $1,801,210 |
| Accounts payable – related parties | 266,009 | - |
| Accrued expenses | 1,869,814 | 2,284,516 |
| Accrued expenses - related parties | - | 188,159 |
| Loans payable - current portion | 1,034,124 | 1,308,516 |
| Derivative liabilities | 58 | 75,381 |
| Total Current Liabilities | 5,062,616 | 5,657,782 |
| Loans payable - noncurrent portion | 19,936 | 31,189 |
| Deferred tax liability | 304,657 | 2,617,359 |
| Total Liabilities | 5,387,209 | 8,306,330 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ (Deficit) Equity: | ||
| Preferred stock, $0.0001 par value; 5,000,000 shares authorized; (see designations and shares authorized for Series A, Class C and Class K preferred stock) | ||
| Class C Preferred Stock; 1 share authorized, issued and outstanding at December 31, 2023 and 2022 | - | - |
| Class K Preferred Stock; 1 share authorized, issued and outstanding at December 31, 2023 and 2022 | - | - |
| Common stock, $0.0001 par value; 100,000,000 shares authorized; 534,719 and 197,209 shares issued and outstanding at December 31, 2023 and 2022, respectively | 54 | 20 |
| Additional paid-in capital | 130,117,209 | 121,637,966 |
| Accumulated other comprehensive income | (2,901,339) | (2,885,523) |
| Accumulated deficit | (127,343,657) | (107,408,545) |
| Total Stockholders’ (Deficit) Equity | (127,733) | 11,343,918 |
| Total Liabilities and Stockholders’ Equity | $5,259,476 | $19,650,248 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.